Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Heidelberg Pharma AG    WL6   DE000A11QVV0

HEIDELBERG PHARMA AG (WL6)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
01/15/2018 01/16/2018 01/17/2018 01/18/2018 01/19/2018 Date
3.91(c) 3.65(c) 3.38(c) 3.4(c) 3.42(c) Last
127 802 115 840 104 445 22 175 14 109 Volume
+8.61% -6.65% -7.40% +0.59% +0.59% Change
More quotes
Financials (€)
Sales 2017 3,49 M
EBIT 2017 -9,67 M
Net income 2017 -8,73 M
Finance 2017 28,0 M
Yield 2017 -
Sales 2018 4,99 M
EBIT 2018 -9,04 M
Net income 2018 -10,2 M
Finance 2018 25,6 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 13,8x
EV / Sales2018 10,2x
Capitalization 76,3 M
More Financials
Company
Heidelberg Pharma AG engages in the development of diagnostic and therapeutic products for the detection and targeted treatment of various types of cancer.It operates through the following segments: Customer Specific Research (Cx), Diagnostics (Dx) and Therapeutics (Rx).The Customer Specific... 
More about the company
Surperformance© ratings of Heidelberg Pharma AG
Trading Rating : Investor Rating :
More Ratings
Latest news on HEIDELBERG PHARMA AG
01/08 HEIDELBERG PHARMA : and Advanced Proteome Therapeutics Progress Collaborative Pr..
2017 HEIDELBERG PHARMA AG : Release according to Article 26, Section 1 of the WpHG [t..
2017 HEIDELBERG PHARMA AG : Release according to Article 26, Section 1 of the WpHG [t..
2017 HEIDELBERG PHARMA AG : Release according to Article 26, Section 1 of the WpHG [t..
2017 HEIDELBERG PHARMA AG : Release according to Article 26, Section 1 of the WpHG [t..
2017 HEIDELBERG PHARMA AG : Notification and public disclosure of transactions by per..
2017 HEIDELBERG PHARMA AG : Notification and public disclosure of transactions by per..
2017 HEIDELBERG PHARMA AG : Notification and public disclosure of transactions by per..
2017 HEIDELBERG PHARMA AG : Notification and public disclosure of transactions by per..
2017 HEIDELBERG PHARMA AG : Notification and public disclosure of transactions by per..
More news
Sector news : Biotechnology & Medical Research - NEC
01/17 CELGENE : Conducts Deal Talks With Juno -- WSJ
01/16 CELGENE : in Talks to Buy Juno Therapeutics -- Update
01/16 CELGENE : in Talks to Buy Juno Therapeutics
01/12 Drugmakers see a pricing blueprint in an $850,000 gene therapy
01/12 SPARK'S PRICE FOR LUXTURNA BLINDNESS : Icer
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
2017WILEX AG successfully completes change of name to Heidelberg Pharma AG  
2017WILEX AG: Interim management statement for the first nine months of 2017  
2017WILEX AG: Interim management statement for the first nine months of 2017  
2017WILEX AG: Interim management statement for the first nine months of 2017  
2017WILEX : Announces Adjustment of Guidance  
More tweets
Qtime:25
News from SeekingAlpha
2016 Deal Flurry Shines Spotlight On Novel Multiple Myeloma Target
Chart HEIDELBERG PHARMA AG
Duration : Period :
Heidelberg Pharma AG Technical Analysis Chart | WL6 | DE000A11QVV0 | 4-Traders
Technical analysis trends HEIDELBERG PHARMA AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 3,87 €
Spread / Average Target 14%
EPS Revisions
Managers
NameTitle
Christof Hettich Chairman-Supervisory Board
Friedrich von Bohlen und Halbach Member-Supervisory Board
Georg F. Baur Deputy Chairman-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
HEIDELBERG PHARMA AG4.65%94
CELLTRION, INC.--.--%37 510
IQVIA HOLDINGS INC2.37%20 782
LONZA GROUP0.76%20 640
INCYTE CORPORATION-4.65%19 399
ALNYLAM PHARMACEUTICALS, INC.-1.42%12 192